Differences

This shows you the differences between two versions of the page.

--- groups:relogio:research [2014/11/06 21:33] – relogio
+++ groups:relogio:research [2016/06/22 11:12] (current) – removed schuppner
@@ Line 1: / Line 1: @@
-**[[groups:relogio:home]] |[[groups:relogio:research]] |[[groups:relogio:people]] |[[groups:relogio:internal]] |[[groups:relogio:publications]] |[[groups:relogio:news and events]]   |[[groups:relogio:open positions]] |[[groups:relogio:contact]] |**
-====== research ======
-===== The mammalian Circadian Clock  =====
-All cells hold an internal clock able to generate daily-endogenous rhythms. These endogenous rhythms are detected in 10% of all genes [1] and provide a way to react to external clues, to anticipate behaviour and to adapt molecular processes to specific day-times . Malfunctions of the circadian clock have been reported in the context of many diseases and disorders. Cancer is one such disease, although the mechanisms involved are not yet clear. Clock-controlled genes (CCGs) are involved in many molecular processes essential for malignant transformation of tumour cells [2]. The coupling of the circadian system to tumour progression is still an unexploited field of research. We use a systems biology approach involving wet-lab experiments, including genome wide screening of gene expression of human cell lines and tissues bioinformatics, and computational models,  to understand the dynamic interplay between cancer and the clock [3].
-{{ :groups:relogio:bild2.jpg?600|}}
-With such a methodology we wish to answer the following questions:
-How are the pathways, which connect the circadian clock to cancer, regulated?
-Is this regulation specific for different stages of tumour progression?
-Can a circadian signature for tumour progression be defined?
-With our research, we expect to be able to provide valuable insights into the mechanism of circadian regulation of tumourigenesis per se and to contribute to a better understanding of the cancer-clock system. As a perspective, our group  hopes to contribute with valuable information to the improvement of diagnosis and prognosis in cancer, potentialy leading to the identification of novel drug-targets and optimization of therapy.
-. T. Bollinger, U. Schibler, Swiss Med Wkly. (2014)  [[http://www.ncbi.nlm.nih.gov/pubmed/25058693|PMID: 25058693]]
-. S. Sahar, P. Sassone-Corsi, Nat Rev Cancer 9, 886 (2009) [[http://www.ncbi.nlm.nih.gov/pubmed/19935677|PMID:
-    19935677]]
-. A. Relógio, //et al//., PLoS Genet (2014) [[http://www.ncbi.nlm.nih.gov/pubmed/24875049|PMID: 24875049]]